JP2022008403A5 - - Google Patents

Download PDF

Info

Publication number
JP2022008403A5
JP2022008403A5 JP2021150116A JP2021150116A JP2022008403A5 JP 2022008403 A5 JP2022008403 A5 JP 2022008403A5 JP 2021150116 A JP2021150116 A JP 2021150116A JP 2021150116 A JP2021150116 A JP 2021150116A JP 2022008403 A5 JP2022008403 A5 JP 2022008403A5
Authority
JP
Japan
Prior art keywords
composition
volume
weight
mass
vision
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021150116A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022008403A (ja
JP7470667B2 (ja
Filing date
Publication date
Priority claimed from JP2020559558A external-priority patent/JP6946575B2/ja
Application filed filed Critical
Publication of JP2022008403A publication Critical patent/JP2022008403A/ja
Publication of JP2022008403A5 publication Critical patent/JP2022008403A5/ja
Priority to JP2024062082A priority Critical patent/JP2024096131A/ja
Application granted granted Critical
Publication of JP7470667B2 publication Critical patent/JP7470667B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021150116A 2018-04-24 2021-09-15 眼の状態の治療のためのピロカルピン塩酸塩の使用 Active JP7470667B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024062082A JP2024096131A (ja) 2018-04-24 2024-04-08 眼の状態の治療のためのピロカルピン塩酸塩の使用

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201862662144P 2018-04-24 2018-04-24
US62/662,144 2018-04-24
US201862780117P 2018-12-14 2018-12-14
US62/780,117 2018-12-14
US201962790957P 2019-01-10 2019-01-10
US62/790,957 2019-01-10
JP2020559558A JP6946575B2 (ja) 2018-04-24 2019-04-24 眼の状態の治療のためのピロカルピン塩酸塩の使用
PCT/US2019/028917 WO2019209955A2 (en) 2018-04-24 2019-04-24 Presbyopia treatments

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020559558A Division JP6946575B2 (ja) 2018-04-24 2019-04-24 眼の状態の治療のためのピロカルピン塩酸塩の使用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024062082A Division JP2024096131A (ja) 2018-04-24 2024-04-08 眼の状態の治療のためのピロカルピン塩酸塩の使用

Publications (3)

Publication Number Publication Date
JP2022008403A JP2022008403A (ja) 2022-01-13
JP2022008403A5 true JP2022008403A5 (cg-RX-API-DMAC7.html) 2022-05-06
JP7470667B2 JP7470667B2 (ja) 2024-04-18

Family

ID=66821312

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020559558A Active JP6946575B2 (ja) 2018-04-24 2019-04-24 眼の状態の治療のためのピロカルピン塩酸塩の使用
JP2021150116A Active JP7470667B2 (ja) 2018-04-24 2021-09-15 眼の状態の治療のためのピロカルピン塩酸塩の使用
JP2024062082A Pending JP2024096131A (ja) 2018-04-24 2024-04-08 眼の状態の治療のためのピロカルピン塩酸塩の使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020559558A Active JP6946575B2 (ja) 2018-04-24 2019-04-24 眼の状態の治療のためのピロカルピン塩酸塩の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024062082A Pending JP2024096131A (ja) 2018-04-24 2024-04-08 眼の状態の治療のためのピロカルピン塩酸塩の使用

Country Status (25)

Country Link
US (4) US10610518B2 (cg-RX-API-DMAC7.html)
EP (2) EP3681500B2 (cg-RX-API-DMAC7.html)
JP (3) JP6946575B2 (cg-RX-API-DMAC7.html)
KR (2) KR20230079489A (cg-RX-API-DMAC7.html)
CN (1) CN112272558A (cg-RX-API-DMAC7.html)
AU (3) AU2019261598B9 (cg-RX-API-DMAC7.html)
BR (1) BR112020021845A2 (cg-RX-API-DMAC7.html)
CA (2) CA3074618C (cg-RX-API-DMAC7.html)
CL (1) CL2020002734A1 (cg-RX-API-DMAC7.html)
CO (1) CO2020014563A2 (cg-RX-API-DMAC7.html)
CY (1) CY1125325T1 (cg-RX-API-DMAC7.html)
DK (1) DK3681500T3 (cg-RX-API-DMAC7.html)
ES (1) ES2920803T5 (cg-RX-API-DMAC7.html)
HR (1) HRP20220762T1 (cg-RX-API-DMAC7.html)
HU (1) HUE058931T2 (cg-RX-API-DMAC7.html)
IL (1) IL278178A (cg-RX-API-DMAC7.html)
LT (1) LT3681500T (cg-RX-API-DMAC7.html)
MX (1) MX2020011301A (cg-RX-API-DMAC7.html)
PH (1) PH12020551766A1 (cg-RX-API-DMAC7.html)
PL (1) PL3681500T3 (cg-RX-API-DMAC7.html)
PT (1) PT3681500T (cg-RX-API-DMAC7.html)
RS (1) RS63360B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202010472XA (cg-RX-API-DMAC7.html)
SI (1) SI3681500T1 (cg-RX-API-DMAC7.html)
WO (1) WO2019209955A2 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7274475B2 (ja) 2017-07-20 2023-05-16 セインダ ファーマシューティカル グアンジョウ コーポレイション 近視の処置のための組成物および方法
US20210251970A1 (en) 2018-10-10 2021-08-19 Presbyopia Therapies Inc Compositions and methods for storage stable ophthalmic drugs
US12161629B2 (en) 2018-10-15 2024-12-10 Opus Genetics, Inc. Methods and compositions for treatment of glaucoma and related conditions
CN113164452A (zh) 2018-10-26 2021-07-23 奥库菲尔制药股份有限公司 治疗老花眼、散瞳和其他眼部疾病的方法和组合物
EP4210690B1 (en) * 2020-09-11 2025-01-29 Intratus-Nevada, Inc. Compositions and methods for treating presbyopia, hyperopia, astigmatism, decreased stereopsis, and decreased contrast sensitivity
CA3210064A1 (en) * 2021-01-28 2022-08-04 Glaukos Corporation Formulations
WO2022232205A1 (en) * 2021-04-28 2022-11-03 Lenz Therapeutics, Inc. A method of reducing brow ache
CN115368310B (zh) 2021-05-18 2025-06-27 奥库菲尔医药公司 合成甲磺酸酚妥拉明的方法
US12180206B2 (en) 2021-11-17 2024-12-31 Lenz Therapeutics Operations, Inc. Aceclidine derivatives, compositions thereof and methods of use thereof
WO2023125544A1 (zh) 2021-12-28 2023-07-06 沈阳兴齐眼药股份有限公司 组合物及其在制备用于治疗老花眼的药物中的用途
US11857538B2 (en) 2022-01-14 2024-01-02 Somerset Therapeutics, Llc Stable pilocarpine formulations with modified buffer characteristics and related methods
US11969410B2 (en) 2022-02-09 2024-04-30 Somerset Therapeutics, Llc Low pH pilocarpine and brimonidine compound formulations and related methods
CN119584954A (zh) 2022-04-21 2025-03-07 格劳科斯公司 眼用局部乳膏组合物
US20230372303A1 (en) 2022-05-18 2023-11-23 Glaukos Corporation Applications of zwitterions in ophthalmic topical cream compositions and preparations
CN117243888A (zh) * 2023-09-22 2023-12-19 南京海纳制药有限公司 一种含有盐酸毛果芸香碱滴眼水性药物组合物及其制备方法
US12414942B1 (en) 2024-03-15 2025-09-16 Lenz Therapeutics Operations, Inc. Compositions, methods, and systems for treating presbyopia

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474751A (en) 1983-05-16 1984-10-02 Merck & Co., Inc. Ophthalmic drug delivery system utilizing thermosetting gels
US4851521A (en) 1985-07-08 1989-07-25 Fidia, S.P.A. Esters of hyaluronic acid
CA2003198C (en) 1988-11-29 1995-03-21 Anthony J. Dziabo, Jr. Aqueous ophthalmic solutions and method for preserving same
US5122522A (en) 1989-06-21 1992-06-16 The Trustees Of The University Of Pennsylvania Treatment and control of ocular development
US5055467A (en) 1989-11-13 1991-10-08 Allergan, Inc. Pharmaceutical epinephrine-pilocarpine compounds
US5496471A (en) 1990-01-08 1996-03-05 Ciba-Geigy Corporation Apparatus for removing components from solutions
US5776916A (en) 1990-07-10 1998-07-07 Gramer; Eugen Medicament for reducing the intraocular pressure
CA2064160C (en) 1991-03-27 1998-08-11 Paul J. T. Missel Use of combinations of gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US5459133A (en) 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
JPH07508751A (ja) 1992-07-02 1995-09-28 テラー・オフサルミック・ファーマシューティカルズ・インコーポレーテッド 老視治療のための方法および生産品
SE512871C2 (sv) 1992-08-20 2000-05-29 Santen Oy Oftalmologisk beredning innehållande pilokarpin och ytterligare medel för behandling av okular hypertension
AU5599594A (en) * 1992-11-16 1994-06-08 Ciba-Geigy Ag Polyvinyl alcohol/borate ophthalmic drug delivery system
US5422116A (en) 1994-02-18 1995-06-06 Ciba-Geigy Corporation Liquid ophthalmic sustained release delivery system
SE9401109D0 (sv) * 1994-03-31 1994-03-31 Leiras Oy Opthalmic composition II
US5574518A (en) 1995-01-10 1996-11-12 Les Laboratoires Opti-Centre Inc. System incorporation two different sphero-non-spherical contact lenses for correcting presbytia
US5612027A (en) 1995-04-18 1997-03-18 Galin; Miles A. Controlled release of miotic and mydriatic drugs in the anterior chamber
US6291466B1 (en) * 1998-07-30 2001-09-18 Allergan Sales, Inc. Cholinergic agents in the treatment of presbyopia
US6164282A (en) 1999-01-27 2000-12-26 Allergan Sales, Inc. Methods for restoring and/or enhancing accommodation in pseudo phakia
CH693625A5 (it) 1999-02-18 2003-11-28 Inpharma Sa Composizioni farmaceutiche contenenti composti ad attività promotrice di assorbimento di principi attivi.
IT1306135B1 (it) 1999-04-26 2001-05-30 Farmigea Spa Composizioni oftalmiche per il trattamento delle turbe visivecaratterizzate da ridotta sensibilita' al contrasto.
AU7581000A (en) 1999-09-16 2001-04-17 Gerald D. Horn A method for optimizing pupil size using alpha antagonist
US6420407B1 (en) 1999-09-16 2002-07-16 Gerald Horn Ophthalmic formulation which modulates dilation
TWI227143B (en) 1999-12-15 2005-02-01 Guo-Jiun Sung In situ gel formation for ophthalmic delivery by combining Pluronic/Carbopol medic composition and its preparing method
US6218428B1 (en) 2000-04-28 2001-04-17 Emil Chynn Ophthalmic composition
PE20020146A1 (es) 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
WO2002024116A1 (en) 2000-09-20 2002-03-28 Shahinian, Lee, Jr. Self-preserved nasal, inhalable, and topical ophthalmic preparations and medications
US6273092B1 (en) 2000-09-22 2001-08-14 Gerard M. Nolan Methods for treating various eye disorders
ITMI20010708A1 (it) 2001-04-03 2002-10-03 Alessandro Randazzo Trattamento farmacologico degli aloni notturni e delle immagini fantasma con parasimpaticomimetici diluiti aceclidina/pilocarpina dopo inter
US20030139737A1 (en) 2002-01-24 2003-07-24 J.T. Lin Method and apparatus for treatment of presbyopia by lens relaxation and anterior shift
CA2493581C (en) 2002-07-30 2014-12-23 Omeros Corporation Ophthalmologic irrigation solutions and method
US20070211212A1 (en) 2002-09-26 2007-09-13 Percy Bennwik Eye state sensor
US20050261641A1 (en) 2002-09-26 2005-11-24 Warchol Mark P Method for ophthalmic administration of medicament
US20040078009A1 (en) 2002-10-17 2004-04-22 Lin J. T. Method and apparatus for the treatment of presbyopia and other eye disorders combining pharmocological and surgical means
US20050205101A1 (en) * 2002-10-17 2005-09-22 Lin J T Combined pharmocological and surgical method and system for the treatment of eye disorders
US20060177430A1 (en) 2002-12-20 2006-08-10 Chakshu Research Inc Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer
EP1592435A4 (en) 2002-12-20 2008-01-23 Chakshu Res Inc EYE FORMULATION FOR THE PREVENTION AND TREATMENT OF EYE DRESS
EP2163643B1 (en) 2003-03-05 2015-01-21 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US20050119262A1 (en) 2003-08-21 2005-06-02 Pharmacia Corporation Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
PL1754491T3 (pl) 2004-05-21 2010-08-31 Senju Pharma Co Preparat do oczu do wchłaniania przezskórnego zawierający agonistę receptora muskarynowego
US20050279369A1 (en) 2004-06-21 2005-12-22 Lin J T Method and apparatus for the treatment of presbyopia and glaucoma by ciliary body ablation
CA2614519A1 (en) 2004-10-22 2006-05-04 Omer Yilmaz System and method for aligning an optic with an axis of an eye
BRPI0615432A2 (pt) 2005-09-02 2011-05-17 Theravida Inc composição farmacêutica, e, uso de compostos
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
DK2038252T3 (en) 2006-07-12 2016-12-19 Univ Tennessee Res Found SUBSTITUTED AND ACYLANILIDER methods of use thereof
ATE439863T1 (de) 2006-12-18 2009-09-15 Jorge Luis Benozzi Ophthalmische zusammensetzungen von parasympathischen stimulantia und entzündungshemmer zur verwendung bei der behandlung von presbyopie
WO2009046967A1 (en) 2007-10-08 2009-04-16 Fovea Pharmaceuticals Sa Aqueous ophthalmic formulations
AU2015202175A1 (en) 2007-12-15 2015-05-14 Anant Sharma Optical correction
GB0724558D0 (en) 2007-12-15 2008-01-30 Sharma Anant Optical correction
WO2010125416A1 (en) 2009-04-27 2010-11-04 Raouf Rekik Drug delivery to the anterior and posterior segments of the eye
WO2010135731A1 (en) 2009-05-22 2010-11-25 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
US8299079B2 (en) 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
TW201109325A (en) 2009-07-30 2011-03-16 Wakamoto Pharma Co Ltd Aqueous composition for eye drops
AR081049A1 (es) 2010-08-17 2012-06-06 Gonzalez Santos Alejandro Raul Medicamento oftalmico para el tratamiento de la hipermetropia
US9119772B2 (en) * 2011-01-26 2015-09-01 Allergan, Inc. Androgen composition for treating an opthalmic condition
UA113525C2 (xx) 2011-09-20 2017-02-10 Спосіб лікування пресбіопії
AU2012322917B2 (en) 2011-10-12 2016-11-03 Ascendis Pharma Ophthalmology Division A/S Prevention and treatment of ocular conditions
US20130157963A1 (en) 2011-12-16 2013-06-20 Allergan, Inc. Ophthalmic compositions comprising polyvinyl capralactam-polyvinyl acetate-polyethylene glycol graft copolymers
EP2630952A1 (en) 2012-02-23 2013-08-28 Novagali Pharma S.A. Self-preserved oil dispersions comprising boric acid
US10507245B2 (en) 2012-07-19 2019-12-17 Luis Felipe Vejarano Restrepo Ophthalmic formulation and method for ameliorating presbyopia
EP2950800B1 (en) 2013-02-01 2020-09-09 Ocuphire Pharma, Inc. Methods and compositions for daily ophthalmic administration of phentolamine to improve visual performance
US9795560B2 (en) 2013-02-01 2017-10-24 Ocularis Pharma, Llc Aqueous ophthalmic solutions of phentolamine and medical uses thereof
US9089562B2 (en) 2013-08-28 2015-07-28 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
US9968594B2 (en) 2013-08-28 2018-05-15 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
US9314427B2 (en) 2013-08-28 2016-04-19 Presbyopia Therapies Llc Compositions and methods for the improvement of distance vision and the treatment of refractive errors of the eye
US8859623B1 (en) 2013-11-14 2014-10-14 Paragon BioTeck, Inc. Methods and compositions of stable phenylephrine formulations
ES2538551B1 (es) 2013-12-20 2016-01-13 Eurocanarias Oftalmológica, Sl Composición Oftálmica para la corrección de la presbicia
EP3750541A1 (en) 2014-01-10 2020-12-16 Santen Pharmaceutical Co., Ltd Pharmaceutical preparation containing pyridylaminoacetic acid compound
AU2014382677A1 (en) 2014-02-11 2016-09-01 Orasis Pharmaceuticals Ltd. Pharmacological ophthalmic composition for use in the correction of presbyopia and its administration
US11052094B2 (en) 2015-05-29 2021-07-06 Sydnexis, Inc. D2O stabilized pharmaceutical formulations
US20190000808A1 (en) 2015-07-13 2019-01-03 Allergan, Inc. Composition and methods for the treatment of blephopharoptosis
CH711969A2 (it) 2015-12-29 2017-06-30 Pinelli Roberto Composizione per il trattamento della presbiopia.
US10231968B2 (en) 2016-08-01 2019-03-19 David R. Hardten Medicinal solution to be continuously or pulse-delivered to the eye for treating ophthalmological conditions/maladies
WO2018033792A2 (en) 2016-08-19 2018-02-22 Orasis Pharmaceuticals Ltd. Ophthalmic pharmaceutical compositions and uses relating thereto
EP3525885B1 (en) 2016-10-12 2022-01-26 PS Therapy Ltd. Artificial tear, contact lens and drug vehicle compositions and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2022008403A5 (cg-RX-API-DMAC7.html)
HRP20220762T1 (hr) Upotreba pilokarpin-hidroklorida u liječenju prezbiopije
WO2008011836A3 (es) Soluciones oftálmicas
ES2212131T3 (es) Composiciones farmaceuticas con actividad antimicrobiana.
ATE511847T1 (de) Pharmazeutische zubereitung für die behandlung entzündlicher erkrankungen des urogenitaltraktes
NZ613291A (en) Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
CH711969A2 (it) Composizione per il trattamento della presbiopia.
JP2020531511A5 (cg-RX-API-DMAC7.html)
CN108261390A (zh) 一种布林佐胺溴莫尼定滴眼液及其制备方法
JP6770436B2 (ja) 高浸透圧ヒアルロン酸組成物
CA2468664A1 (en) Ketorolac tromethamine compositions for treating or preventing ocular pain
JP2009500397A5 (cg-RX-API-DMAC7.html)
JP2009500398A5 (cg-RX-API-DMAC7.html)
ES2754449T3 (es) Acido carboxílico de pirrolidona (pca) para uso oftálmico
CA2758858C (en) Aqueous ophthalmic compositions containing anionic therapeutic agents
RU2019118904A (ru) Распределение в глазу и фармакокинетика композиций лифитеграста
IL273213B1 (en) Topical preparations of chloroprocaine
US20180147140A1 (en) Treatment and Prevention of ENT Infections
MX2022006523A (es) Composicion que comprende budesonida para uso oftalmico.
BRPI0410576A (pt) composto quìmico, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método para o tratamento, prevenção ou alìvio de uma doença ou um distúrbio ou condição de um corpo de animal vivo
CN101467963A (zh) 治疗干眼病的眼药水
CN108348457A (zh) 无菌水性眼用溶液的治疗用途
CN102349910B (zh) 一种复方眼科药物组合物及其制备方法
JP2013523831A5 (cg-RX-API-DMAC7.html)
JP2005239682A (ja) 眼科用剤